Full Breakdown
New RAPID Coverage Pathway Aims to Expedite Medicare Access to Breakthrough Medical Devices
4/24/2026, 8:15:20 AM
Overview of the RAPID Coverage Pathway
The Trump administration has introduced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, designed to accelerate Medicare coverage for breakthrough medical devices. Announced by the Centers for Medicare and Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA), this new program focuses on FDA-designated Class II and Class III devices, aiming to streamline the reimbursement process for medical device manufacturers.
Key Features of the RAPID Program
The RAPID pathway allows for Medicare coverage to be granted within 60 to 90 days following FDA approval of qualifying devices. John Brooks, CMS Deputy Director, emphasized that the program fosters unprecedented collaboration between CMS and the FDA, enabling manufacturers to receive guidance early in the development process. This coordination is intended to align evidence generated for FDA review with Medicare coverage decisions, thereby reducing delays that have historically occurred between FDA market authorization and Medicare coverage determinations.
Eligibility and Implementation
Devices eligible for the RAPID pathway must be part of an Investigational Device Exemption (IDE) study that enrolls Medicare beneficiaries and focuses on clinical health outcomes agreed upon by both the FDA and CMS. Grace Graham, FDA Deputy Commissioner, noted that the RAPID program addresses unmet medical needs among Medicare beneficiaries and aims to facilitate a more efficient coverage process. Currently, 40 devices qualify for this pathway, with an additional 20 expected to participate.
Transition from Previous Programs
The RAPID program replaces the Transitional Coverage for Emerging Technologies (TCET) program, which had limitations on the number of products covered annually. Under TCET, CMS capped coverage to approximately five products each year, while the RAPID pathway is designed to enhance transparency and provide clearer targets for device manufacturers. This shift is seen as a response to criticisms regarding the time lag between FDA approval and CMS coverage decisions.
Official Statements on the RAPID Pathway
CMS Administrator Dr. Mehmet Oz stated, “FDA and CMS each play a critical role in getting new medical devices to patients, and they work most effectively when aligned sooner in that process.” He highlighted that the RAPID coverage pathway facilitates earlier collaboration, thereby cutting red tape for innovators and expediting access to life-changing health technologies for beneficiaries.
Criticism and Opposition
Despite the positive outlook from officials, some stakeholders in the medical device market have expressed concerns regarding the previous TCET program's inefficiencies. Critics argue that the lack of early collaboration between CMS and device manufacturers led to misalignment in data generation for Medicare coverage determinations. This historical context underscores the importance of the RAPID pathway's approach to integrating FDA and CMS processes.
Conclusion
The RAPID coverage pathway represents a significant shift in how Medicare addresses breakthrough medical devices, aiming to enhance access for beneficiaries while fostering a more efficient collaboration between regulatory bodies. As the program is implemented, it will be closely monitored for its effectiveness in reducing delays and improving the alignment of evidence expectations in the medical device approval process.
